MedTrace Logo

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

NCT04660812 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2025-10-20

No results posted yet for this study

Summary

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

Conditions

Interventions

DRUG

AB680

AB680 is a cluster of differentiated CD73 Inhibitor

DRUG

Etrumadenant

Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist

DRUG

Zimberelimab

Zimberelimab is a fully human anti-PD-1 monoclonal antibody

DRUG

Bevacizumab

Bevacizumab is administered as part of standard chemotherapy regimen

DRUG

m-FOLFOX-6 regimen

mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen

DRUG

Regorafenib

Regorafenib is administered as part of standard chemotherapy regimen

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Arcus Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2025-09-05
Completion
2025-09-05
FDA Drug
Yes

Countries

  • United States
  • France
  • Italy
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04660812 on ClinicalTrials.gov